Opinion|Videos|February 7, 2025
GOLD 2025 Report: Ensifentrine, a New Treatment in COPD
Panelists discuss how ensifentrine is a nebulized inhaled therapy, a small molecule inhibitor of PDE3 and PDE4, and is compelling because there are very few adverse effects. There are also compelling results from studies that show bronchial dilatation and exacerbation reduction.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- The most impactful changes to the 2025 GOLD Report pertain to chronic obstructive pulmonary disease (COPD) management, specifically the addition of 2 new treatment options, ensifentrine and dupilumab, that were approved for use by the FDA in June 2024 and September 2024, respectively.
- What is ensifentrine (first-in-class PDE3 and PDE4 inhibitor), and how do its effects translate for the management of stable COPD?
Advertisement
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Advertisement
Advertisement
Trending on HCPLive
1
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
2
Targeting the Disease Mechanism in PFIC, With Hisamitsu Hayashi, PhD
3
Residual Asthma Exacerbations on Biologics Vary by Mechanism
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5